Home
>
National Drug Code (NDC)
>
BENLYSTA
BENLYSTA - 49401-101-01 - (belimumab)
Drug Information of BENLYSTA
| Product NDC: | 49401-101 |
| Proprietary Name: | BENLYSTA |
| Non Proprietary Name: | belimumab |
| Active Ingredient(s): | 120 mg/1.5mL & nbsp; belimumab |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of BENLYSTA
| Product NDC: | 49401-101 |
| Labeler Name: | Human Genome Sciences, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA125370 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20110310 |
Package Information of BENLYSTA
| Package NDC: | 49401-101-01 |
| Package Description: | 1 VIAL in 1 CARTON (49401-101-01) > 1.5 mL in 1 VIAL |
NDC Information of BENLYSTA
| NDC Code | 49401-101-01 |
| Proprietary Name | BENLYSTA |
| Package Description | 1 VIAL in 1 CARTON (49401-101-01) > 1.5 mL in 1 VIAL |
| Product NDC | 49401-101 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | belimumab |
| Dosage Form Name | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20110310 |
| Marketing Category Name | BLA |
| Labeler Name | Human Genome Sciences, Inc. |
| Substance Name | BELIMUMAB |
| Strength Number | 120 |
| Strength Unit | mg/1.5mL |
| Pharmaceutical Classes | Decreased B Lymphocyte Activation [PE],B Lymphocyte Stimulator-specific Inhibitor [EPC],B Lymphocyte Stimulator-directed Antibody Interactions [MoA] |
